Pharmaceuticals, Biotechnology & Life Sciences

Shenqi Pharmaceutical’s August 2026 surge: 1.5 billion CNY turnover, 3.43% rise, amid market dips and abnormal trading alerts.

Goldman Sachs spots hedge funds eyeing French biotech Abivax for its anti‑viral pipeline in emerging markets—investors see high‑growth potential beyond the U.S.

Uni‑Bio Science Group’s 1H 2026 report shows HK$273.8 m revenue and strong cash flow amid strategic biopharma expansion and portfolio optimisation.

JNJ’s FDA & EU approvals for Imaavy and Tecvayli boost rare‑anemia and uveal melanoma pipelines, driving growth, dividend strength, and investor confidence.

Fosun Pharmaceutical’s 2026 H1 report shows a sharp earnings jump and strong cash flow, hinting at a valuation rebound driven by strategic BD and biotech innovation.

Inovio Pharmaceuticals struggles with stock volatility and losses, yet pushes ahead with DNA vaccines, anti‑inflammatory drugs, and animal health products.

Explore Rigel Pharmaceuticals’ recent stock rebound, biotech strategy, and pipeline potential for rare immune disorders and cancer.

GSK secures US FDA priority review for Jemperli and Japan’s first approval of Hibsago, boosting its cancer and hepatitis pipeline amid active executive share sales.

Discover how San Diego‑based Belite Bio is tackling macular degeneration, liver disease and diabetes with breakthrough therapeutics—track their volatile stock, market cap, and future growth prospects.

Discover how GRAIL’s liquid‑biopsy tech is reshaping cancer diagnostics and boosting stock performance—key insights for investors and patients alike.